Wills Financial Group’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-3,296
Closed -$705K 60
2022
Q2
$705K Sell
3,296
-349
-10% -$85.3K 0.35% 44
2022
Q1
$1.03M Sell
3,645
-510
-12% -$157K 0.43% 41
2021
Q4
$1.56M Buy
4,155
+1,688
+68% +$656K 0.62% 39
2021
Q3
$1.02M Buy
2,467
+26
+1% +$10.8K 0.46% 41
2021
Q2
$902K Buy
2,441
+320
+15% +$107K 0.39% 45
2021
Q1
$614K Buy
+2,121
New +$590K 0.3% 43

Other funds holding CRL

Wills Financial Group's CRL Position: Q3 2022 in Review

Wills Financial Group sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 3,296 shares — an estimated $705K sold.

Wills Financial Group first reported a position in CRL in Q1 2021 and held it in 6 quarters. The position peaked at $1.56M in Q4 2021. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • Wills Financial Group reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
  • Wills Financial Group sold 3,296 Charles River Laboratories shares in Q3 2022, an estimated $705K.
  • Wills Financial Group first reported a position in Charles River Laboratories in Q1 2021 and held it in 6 quarters.
  • Wills Financial Group's Charles River Laboratories position peaked at $1.56M in Q4 2021.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Wills Financial Group's 13F filing for Q3 2022, filed 14 Nov 2022.